Cancer 2013 July

 

1. Low dose chemotherapeutic drugs without overt cytotoxic effects decrease the secretion of VEGF by cultured human tumor cells: a tentative relationship between drug type and tumor cell type response. Cancer Biomark. 2012-2013;12(3):135-40.

3. MiR-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer ZEB1. Cancer Sci. 2013 Jan;104(1):48-54.

Junseong Park5. TGF-β1 and hypoxia-dependent expression of MKP-1 leads tumor resistance to death receptor-mediated cell death. Cell Death Dis. 2013 Feb 28;4:e521.

 

8. Study of support vector machine and serum surface-enhanced Raman spectroscopy for noninvasive esophageal cancer detection. J Biomed Opt. 2013 Feb;18(2):27008.

10. Selective induction of apoptosis: promising therapy in pancreatic cancer. Curr Pharm Des. 2013;19(12):2259-68.

11. Comparison of treatment results between surgery alone, preoperative short-course radiotherapy, or long-course concurrent chemoradiotherapy in locally advanced rectal cancer. Int J Clin Oncol. 2012 Oct;17(5):482-90.

13. Effect of immunosuppression for primary renal disease on the risk of cancer in subsequent renal transplantation: a population-based retrospective cohort study. Transplantation. 2013 Jan 15;95(1):122-7.

15. Adoptive transfer of siRNA Cblb-silenced CD8+ T lymphocytes augments tumor vaccine efficacy in a B16 melanoma model. PLoS One. 2012;7(9):e44295.

Guenther Lametschwandtner-1

20. Tumour necrosis factor alpha down-regulates the expression of peroxisome proliferator activated receptor alpha (PPARα) in human hepatocarcinoma HepG2 cells by activation of NF-κB pathway. Cytokine. 2013 Jan;61(1):266-74.

22. Chaperonopathies and chaperonotherapy. Hsp60 as therapeutic target in cancer: potential benefits and risks. Curr Pharm Des. 2013;19(3):452-7.

23. Initial safety and outcomes of miriplatin plus low-dose epirubicin for transarterial chemoembolisation of hepatocellular carcinoma. Anticancer Res. 2012 Nov;32(11):5039-44.

25. Results of postoperative radiochemotherapy of the patients with resectable gastroesophageal junction adenocarcinoma in Slovenia. Radiol Oncol. 2012 Dec;46(4):337-45.

27. A novel nonoperative orthotopic colorectal cancer murine model using electrocoagulation. J Am Coll Surg. 2011 Jul;213(1):54-60;

29. Bortezomib for the treatment of previously untreated multiple myeloma. Immunotherapy. 2013 Apr;5(4):327-52.

 

2. PXR and NF-κB correlate with the inducing effects of IL-1β and TNF-α on ABCG2 expression in breast cancer cell lines. Eur J Pharm Sci. 2012 Sep 29;47(2):474-80.

4. Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34⁺ cells in a xenograft model. Breast Cancer Res Treat. 2012 Nov;136(2):457-67.

6. Detection of trastuzumab efficacy using H-1 MRI ex vivo of breast cancer cells. Med Chem Res.2012 Sep;21(9):2316-2319.

7. Composite intestinal adenoma-microcarcinoid clues to diagnosing an under-recognised mimic of invasive adenocarcinoma.  J Clin Pathol. 2013 Apr;66(4):302-6.

Eric RULLIER-19. Low rectal cancer: classification and standardization of surgery. Dis Colon Rectum. 2013 May;56(5):560-7.

 

 

12. Enhanced cellular uptake and gene delivery of glioblastoma with deferoxamine-coated nanoparticle/plasmid DNA/branched polyethylenimine composites. Chemical communications.2013 49(6):549-551.

14. Design and synthesis of (S)- and (R)-enantiomers of [4-(2-hydroxy-1-phenylethylimino)pent-2-ol]dimethyltin(iv) and 2,2-dimethyl-4-phenyl-1,3,2-oxazastannolidine: in vitro antitumor activity against human tumor cell lines and in vivo assay of (S)-enantiomers. Dalton Trans. 2013 Mar 14;42(10):3390-401.

16. Growth of confined cancer spheroids: a combined experimental and mathematical modelling approach. Integr Biol (Camb). 2013 Mar;5(3):597-605.

17. A positive psychological intervention using virtual reality for patients with advanced cancer in a hospital setting: a pilot study to assess feasibility. Support Care Cancer. 2013 Jan;21(1):263-70.

18. Clinicopathological characteristics of hepatocellular carcinoma in Turkey. Asian Pac J Cancer Prev. 2012;13(6):2985-90.

19. CYP3A4 overexpression enhances the cytotoxicity of the antitumor triazoloacridinone derivative C-1305 in CHO cells. Acta Pharmacol Sin. 2013 Jan;34(1):146-56.

Glenn S. Gerhard21. Targeting heme for the identification of cytotoxic agents. Anticancer Agents Med Chem. 2013 Mar;13(3):515-22.






24. New therapeutic strategy for treating otitis media with effusion in postirradiated nasopharyngeal carcinoma patients. J Chin Med Assoc. 2012 Jul;75(7):329-34.

26. Fecal immunochemical tests for colorectal cancer screening. Am J Nurs. 2012 Oct;112(10):67-9.

28. Differential expression of miR-21, miR-125b and miR-191 in breast cancer tissue. Asia Pac J Clin Oncol. 2013 Mar;9(1):53-9.

30. Health-related quality of life among breast cancer patients in Lebanon. Eur J Oncol Nurs. 2012 Dec;16(5):491-7.

Multiselect Ultimate Query Plugin by InoPlugs Web Design Vienna | Webdesign Wien and Juwelier SchönmannMultiselect Ultimate Query Plugin by InoPlugs Web Design Vienna | Webdesign Wien and Juwelier Schönmann